• Find an Expert
  • Contact
  • SearchSearch icon
  • Menu
  • Help
  • Report an issue

Contact


Email

kv@unimelb.edu.au

Credentials


Position
Professor Infectious Diseases
Department of Medicine
Education
PhD
University of New South Wales
Bachelors Degree (Honours)
University of New South Wales
ORCID

0000-0002-1176-5442

Prof Kumar Visvanathan

Professor Infectious Diseases
Department of Medicine

291 Scholarly works
20 Projects

HIGHLIGHTS

  • 2026

    Journal article

    Anti-HBs Immune Complex Levels: A Novel Marker of Hepatitis Flare Following Nucleos(t)ide Analog Withdrawal in HBeAg-negative Chronic Hepatitis B
    DOI: 10.1093/infdis/jiaf569
  • 2026

    Journal article

    Long-Term Follow-Up of Patients in a Prospective Study of NA Discontinuation Identifies Different Patterns of HBsAg Loss
    DOI: 10.1111/apt.70332
  • 2026

    Journal article

    Early Infliximab Levels and Clearance Predict Outcomes After Infliximab Rescue in Acute Severe Ulcerative Colitis: Results From PREDICT-UC
    DOI: 10.1053/j.gastro.2025.07.020
  • 2026

    Journal article

    Monocyte Distribution Width Differentiates Bacterial Enterocolitis from Acute Severe Ulcerative Colitis in the Emergency Department
    DOI: 10.1007/s10620-026-09786-w
  • 2023

    Research grants (ARC, NHMRC, MRFF)

    Novel Monoclonal Antibodies to Treat Chronic Hepatitis B
  • 2023

    Research Grant

    Novel Monoclonal Antibodies to Treat Chronic Hepatitis B
  • 2018

    Research Grant

    Novel Early Detection Strategy for Liver Cancer Using Hepatitis B Splice Variants to Expediate Diagnosis and Improve Treatment Outcome
Kumar Visvanathan

Latest Honours,
Awards and Fellowships


2006
Frank Fenner Award for Advanced Research in Infectious Diseases Australian Society of Infectious Disease
2004
President's Award American Association for the Study of Liver Disease
2001
Fellow of the Royal Australasian College of Physicians (FRACP)
1993
Postgraduate Scholarship NHMRC

RECENT SCHOLARLY WORKS

  • 2025

    Journal article

    Effective real-world outcomes of remdesivir provided under compassionate access for moderate/severe COVID-19 in Australia
    DOI: 10.1111/imj.70173
  • 2025

    Journal article

    Su1880: EARLY SERUM AND FAECAL CYTOKINES PREDICT CLINICAL OUTCOMES IN ACUTE SEVERE ULCERATIVE COLITIS: RESULTS FROM PREDICT-UC
    DOI: 10.1016/s0016-5085(25)02941-5
  • 2025

    Journal article

    DOP057 Early serum and faecal cytokines predict clinical outcomes in Acute Severe Ulcerative Colitis: results from PREDICT-UC
    DOI: 10.1093/ecco-jcc/jjae190.0096
  • 2025

    Journal article

    DOP091 Early serum infliximab levels predict outcomes in Acute Severe Ulcerative Colitis: results from PREDICT-UC
    DOI: 10.1093/ecco-jcc/jjae190.0130
  • 2024

    Journal article

    High end-of-treatment hepatitis B core-related antigen levels predict hepatitis flare after stopping nucleot(s)ide analogue therapy
    DOI: 10.1111/liv.16029
  • 2024

    Journal article

    P404 Monocyte distribution width differentiates bacterial gastroenteritis from Acute Severe Ulcerative Colitis in patients presenting with diarrhoea
    DOI: 10.1093/ecco-jcc/jjad212.0534

RECENT PROJECTS

  • 2023

    Research Grant

    Novel Monoclonal Antibodies to Treat Chronic Hepatitis B
  • 2020

    Research Contracts

    Testing Immune-Mobilising Monoclonal T-Cell Receptors in Chronic Hepatitis B Patient-Derived Liver Organoids

We acknowledge and pay respect to the Traditional Owners of the lands upon which our campuses are situated

Read about our commitment to reconciliation  

About us  

Careers at Melbourne  

Safety and respect  

Newsroom  

Contact  

Phone: 13 MELB ( 13 6352)

International: +61 3 9035 5511


Address:
The University of Melbourne
Grattan Street, Parkville,
Victoria, 3010, Australia


View all Campus locations  
facebookIconlinkedinIconinstagramIcontwitterIcon

Emergency information  |  Disclaimer and copyright  |  Accessibility  |  Privacy  |  VaxFACTS

CRICOS number: 00116K     ABN: 84 002 705 224